leucine rich repeat and fibronectin type III domain containing 2Genealiases: FIGLER2 · KIAA1246 · SALM1
Q-omics provides the consensus-scored LRFN2 profile across patient tissues and cancer cell-line models. LRFN2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LRFN2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LRFN2 RNA expression shows 13,703 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, HNSC, and TGCT as cancer lineages where LRFN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRFN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRFN2 survival associations across molecular data types. LRFN2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRFN2 RNA expression–survival associations across cancer types. High LRFN2 expression shows unfavorable associations in KIRP, UCEC and ACC, but favorable associations in BLCA, UCS and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for LRFN2 RNA expression.
This table summarizes LRFN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LRFN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRFN2 shows lower tumor expression in HNSC, UCEC and READ and higher tumor expression in BRCA, LIHC and BLCA. The HNSC box plot shows higher LRFN2 RNA expression in normal versus tumor tissue (log2 FC = −0.446, t-test p < 0.001).
This table shows molecular features associated with LRFN2 in patient tissues and cancer cell lines. In patient samples, LRFN2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRFN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
